To investigate the expression, role and mechanism of action of long non-coding RNA (lncRNA) ABHD11-AS1 in endometrial carcinoma. The expression of lncRNA ABHD11-AS1 was quantified by qRT-PCR in human endometrial carcinoma (n = 89) and normal endometrial tissues (n = 27). LncRNA ABHD11-AS1 was stably overexpressed or knocked-down in endometrial carcinoma cell lines to examine the cellular phenotype and expression of related molecules. Compared to normal endometrial tissue, lncRNA ABHD11-AS1 was significantly over- cancer. 5 The lncRNA ABHD11-AS1 has been found to be overexpressed in gastric cancer, 6 ovarian cancer 7 and bladder cancer tissues. 8 However, the role of ABHD11-AS1 in endometrial cancer has not been reported. Therefore, we investigated the expression, function and mechanism of action of lncRNA ABHD11-AS1 in endometrial carcinoma.
| INTRODUCTION
The incidence of endometrial cancer is increasing year by year.
Endometrial cancer is the second leading cause of deaths due to gynaecological cancer worldwide. 1 Early-stage endometrial cancer has a high survival rate, while approximately 30% of patients are diagnosed with advanced stage disease. cancer. 5 The lncRNA ABHD11-AS1 has been found to be overexpressed in gastric cancer, 6 ovarian cancer 7 and bladder cancer tissues. 8 However, the role of ABHD11-AS1 in endometrial cancer has not been reported. Therefore, we investigated the expression, function and mechanism of action of lncRNA ABHD11-AS1 in endometrial carcinoma.
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| MATERIALS AND METHODS
| Tissue specimens
Twenty-seven normal endometrial specimens that were collected from the normal endometrial tissue of patients with uterine fibroids undergoing hysterectomy, and 89 endometrial carcinomas were collected from patients undergoing surgical resection at the First Affili- sequence could be found in the Table S3 .
| Cell proliferation assays
Cells were trypsinized, seeded into 96-well plates at a density of 3000 cells/well, allowed to adhere, transfected and cultured for 0, 24, 48 or 72 hours. After adding 20 lL of MTT (5 mg/mL), the cells were incubated at 37°C for 2-4 hours, the medium was discarded, and 150 lL of dimethyl sulphoxide (DMSO) was added under dark conditions. Finally, the OD values were measured at 490 nm using a spectrophotometer (BioTek Instruments, Winooski, VT, USA). Each experiment was performed using triplicate wells (at least). 
| Cell cycle assays
| Wound-healing assay
Cells were seeded in six-well plates at a density of 10 6 per well, allowed to adhere, and scratches were created in the monolayers 
| Cell invasion assays
| Real-time PCR
Tissue specimens or cells were placed into microcentrifuge tubes with 1 mL of TRIzol (Takara, Shiga, Japan), the tissues were cut finely, and then the samples were shaken for 30 seconds. Chloroform was added, mixed thoroughly, incubated at room temperature for 10-15 minutes and centrifuged at 14803 g for 20 minutes. The upper layer (500 lL) was transferred to a new microcentrifuge tube;
an equal volume of isopropyl alcohol was added, incubated at À20°C for 30 minutes and centrifuged at 14803 g for 20 minutes;
the supernatant was discarded; 1 mL of 75% ethanol was added and centrifuged at 5782 g for 20 minutes; the supernatant was discarded; and the pellet was air-dried and dissolved in 10 lL of DEPC water. One microlitre of RNA was added to 79 lL of DEPC water, and the OD260/OD280 ratio was assessed to determine RNA concentration and quality.
Total RNA was reverse transcribed into cDNA using avian myeloblastosis virus transcriptase and random primers (Takara, Shiga, Japan) according to the manufacturer's instructions. The target gene was amplified by real-time quantitative PCR with SYBR Premix Ex Taq TM II kit (Takara). The relative expression of the target genes was determined by comparing the threshold cycle (Ct) values of the target genes to that of 18S rRNA (18S) using the 2 ÀDDCt method (GenePharma).
| Western blotting
Tissue or cell protein samples were extracted, quantified and diluted with 59 loading buffer to the same concentrations, denatured at 
| RNA pull-down assays
Streptavidin beads (BEAVER, Suzhou, China) were used to capture biotin-labelled ABHD11-AS1; IgG was used as a control. The biotinylated nucleic acid compound was incubated with protein lysates prepared from Ishikawa cells transfected with ABHD11-AS1 for 40 minutes in a 42°C water bath to specifically capture ABHD11-AS1 and the corresponding bound proteins. After elution of the beads, the protein samples were detected by Western blotting; the transfected protein in the cell samples was used a positive control;
and IgG was used as a negative control. 
| In vivo tumorigenesis model
| Statistical analysis
Data were analysed using SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA). Correlations were analysed using Spearman's correlation test. Two-tailed t tests were used to compare mean values.
At least three replicates were performed for each group; at least three independent experiments were performed for each assay. All data are expressed as mean AE standard deviation; P < .05 was considered significant.
| RESULTS
| LncRNA ABHD11-AS1 is overexpressed in endometrial carcinoma
Real-time PCR revealed the expression of ABHD11-AS1 was significantly higher in endometrial carcinoma than in normal endometrial tissues ( Figure 1A , P < .05). The MTT assay revealed that overexpression of ABHD11-AS1 significantly increased the proliferation of Ishikawa cells ( Figure 2D , P < .05), whereas knockdown of ABHD11-AS1 using the siRNA significantly decreased the proliferation of HEC-1B cells ( Figure 2E , P < .05).
|
F I G U R E 1 LncRNA ABHD11-AS1 is overexpressed in endometrial carcinoma. ABHD11-AS1 expression was significantly higher in endometrial cancer than in normal endometrial tissues (A). *P < .05 LIU ET AL.
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Cell cycle assays showed that ABHD11-AS1 promoted G1-S progression in Ishikawa cells ( Figure 3A , P < .05) and si-ABHD11-AS1
significantly induced G1 phase arrest in HEC-1B cells ( Figure 3B ,
Apoptosis assays showed that overexpression of ABHD11-AS1 significantly decreased apoptosis in Ishikawa cells ( Figure 3C , P < .05), while knockdown of ABHD11-AS1 significantly increased apoptosis in HEC-1B cells ( Figure 3D , P < .05).
The wound-healing assay and the Transwell assay revealed that ABHD11-AS1 transfection increased the migratory ability and invasive ability ( Figure 4A ,C, P < .05), whereas si-ABHD11-AS1 transfection reduced the migratory ability and invasive ability ( Figure 4B ,D, P < .05).
| LncRNA ABHD11-AS1 promotes endometrial tumorigenicity in vivo
Tumour xenograft volume in nude mice treated with ABHD11-AS1
was greater than that in mock nude mice ( Figure 5A ,B,C, P < .05).
The growth rate was also faster than that in the mock group (Figure 5D , P < .05).
| LncRNA ABHD11-AS1 up-regulates cyclin D1, CDK1, CDK2, CDK4, Bcl-xl and VEGFA and downregulates p16
The protein expression levels of ABHD11-AS1-overexpressing Ishikawa cells were assessed by Western blotting.
Overexpression of ABHD11-AS1 increased the expression of cyclin D1, CDK1, CDK2, CDK4, Bcl-xl and VEGFA and decreased the expression of p16 ( Figure 6A ). Conversely, the opposite results were observed in HEC-1B cells transfected with si-ABHD11-AS1 ( Figure 6A ).
| LncRNA ABHD11-AS1 is coimmunoprecipitated with cyclin D1
RNA pull-down assays were performed to detect the protein that interacted with ABHD11-AS1. Protein from RNA pull-down assays with biotin-labelled ABHD11-AS1 against ABHD11-AS1 was used
for Western blot, which demonstrated an enrichment of cyclin D1 compared with IgG ( Figure 6B ). Western blotting of the xenograft tumour tissues from the nude mouse model showed that overexpression of ABHD11-AS1 increased the expression of cyclin D1, CDK1, CDK2, CDK4, Bcl-xl and VEGFA and decreased the expression of p16 ( Figure 6C ). These observations are consistent with the reported roles of ABHD11-AS1 in gastric cancer, ovarian cancer and bladder. [6] [7] [8] LncRNAs participate in various physiological and pathological processes, including epigenetic regulation and the development of cancer. In addition, lncRNAs have the unique ability to interact directly with both nucleic acids and proteins and have discontinuous effects on many biological processes. 4 Several studies have shown lncRNAs play important roles in the regulation of protein expression. [10] [11] [12] 14 In this study, Western blotting revealed overexpressing ABHD11-AS1 increased the protein levels of cyclin D1, CDK1, CDK2, CDK4, Bcl-xl and VEGFA and decreased the levels of p16, In conclusion, this study reveals ABHD11-AS1 is up-regulated and promotes tumorigenesis in endometrial carcinoma by positively targeting cyclin D1. This is the first demonstration of an oncogenic role for ABHD11-AS1 in endometrial carcinoma; this finding could potentially pave the way for the development of novel strategies for diagnosis and treatment.
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F I G U R E 7 LncRNA ABHD11-AS1 promotes the development of endometrial cancer by targeting cyclin D1. Silencing of cyclin D1 in ABHD11-AS1-overexpressing Ishikawa cells significantly inhibited proliferation (A), induced G1 phase arrest (B) and apoptosis (C), inhibited migration (D) and invasion (E). Western blotting showed that silencing of cyclin D1 reversed the ability of ABHD11-AS1 to up-regulate cyclin D1, CDK1, CDK2, CDK4, Bcl-xl and VEGFA and down-regulate p16 expression (F)
